In short
Clinical trials are investigating ANX007 in people with dry age-related macular degeneration with geographic atrophy. These studies are designed to evaluate safety and efficacy, especially effects on visual function and visual acuity. The main trial listed here is a Phase 3 study in 630 participants.
Key points
- Clinical trials of ANX007 are studying people with dry age-related macular degeneration and geographic atrophy, a serious eye condition that can affect central vision. The listed trial is a Phase 3 study, which means it is a late-stage trial in a larger group of participants. Researchers are looking at safety and efficacy, with a focus on visual function and visual acuity. The main endpoint measures whether participants lose 15 or more letters on the best corrected vision test by Month 15. The study plans to include 630 participants and is currently authorised.
Trial overview
The listed clinical trial is studying ANX007 in people with dry age-related macular degeneration (AMD) with geographic atrophy (GA). This is an interventional study, which means researchers are giving a treatment and then measuring the results. The trial is authorised and is designed to evaluate both efficacy and safety.
Who the study is for
This study is for participants with dry AMD and GA. These are eye conditions that can damage the macula, the part of the eye needed for sharp central vision. The trial title also shows that the treatment is given by intravitreal injection, which means an injection into the eye.
The source data do not list the full entry rules, so the exact participation criteria are not available here. In clinical trials, people must meet the study rules before joining.
What the study measures
The main outcome is confirmed best corrected visual acuity (BCVA) loss of 15 letters or more from baseline through Month 15. BCVA is a standard eye test that checks the best vision a person can achieve with glasses or contact lenses if needed. The ETDRS method is the letter-chart system used to measure this outcome.
In simple terms, the study is asking whether vision stays more stable over time after treatment with ANX007. The brief summary also says the study is evaluating effects on visual function and visual acuity.
Study phase and size
This is a Phase 3 trial. Phase 3 studies are usually larger than earlier studies and are used to look more closely at how well a treatment works and how safe it is in a bigger group of people.
The planned enrollment is 630 participants. A larger study size can help researchers better understand the trial results and how consistent they are across participants.
What participation means
People in this trial receive ANX007 as an intravitreal treatment, meaning it is delivered into the eye. The study then follows participants over time and checks vision-related outcomes, especially changes in BCVA through Month 15.
Because only the trial record is available here, details such as visit schedule, extra tests, and the full list of eligibility rules are not provided. The available data do show that the study is focused on a specific eye disease group and is measuring whether vision loss can be limited.